Hers Launches Specialized Menopause and Perimenopause Care to Close Major Healthcare Gap
Hers launched specialty care for menopause/perimenopause, offering women personalized plans including prescription pills, patches, or creams.
/ 38 items
#HIMS↓
BofA Slashes Hims & Hers Q4 Forecast 6.5% Below Street
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.
Novo Nordisk Bets on Telehealth to Relaunch its Weight-Loss Dominance with "Wegovy-in-a-Pill"
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.
Hims falls after FDA posts warning letter
The FDA warned Hims & Hers for misleading ads on compounded weight-loss drugs. Hims claimed "same active ingredient" as FDA-approved drugs like Ozempic, but compounded versions aren't FDA-approved. The FDA says these claims are false and misleading.
FDA Challenges Hims & Hers Over Super Bowl Drug Ad
The FDA criticized Hims & Hers' Super Bowl ad for weight-loss drugs, saying it broke federal law by showing only benefits, not risks. The agency is now boosting enforcement on misleading drug ads, especially for online pharmacies and compounded drugs.
Hims & Hers Revolutionizes Low Testosterone Treatment for Men
Hims & Hers launched affordable, personalized low T treatments to boost energy & sexual health. They offer enclomiphene now, and in 2026, will add FDA-approved oral KYZATREX through a partnership with Marius Pharmaceuticals, plus injectables. Patients start with at-home blood tests.